After doing more diligence and networking, it seems that smaller shops have more relevant research for buyside. I’ve gotten my hands on several BB research, and the quality is quite low vs smaller shops imo (biotech). Three banks in particular have peaked my interest: 1) SVB, 2) LifeSci Capital, and 3) Cowen - fair to prioritize these over the BBs

 
Most Helpful

Stop being a Shimmer shill. Yes, he was top ranked in Smid cap biotech but that doesn’t mean his research is top notch. Seriously, you should asked your buyside clients on what they think of his research. Also Cantor is Cantor. Without a strong IB arm you think they can actually pay anyone else other than Schimmer and Schmidt? No, IB deals won’t just increase 10x because they’re there. Do you really think IB bankers depend on ER to do IPOs and follow-on? And working for him won’t give you a better chance going to buyside than working for a low/no ranked analyst at a strong BB. In the end, you will get looks by working at a well known firm regardless of who you work for. A serious advice for op, do not choose Cantor over JPM/MS or other respected BB/MM.

 

IDK what you're smoking. Schimmer well regarded on buyside. If a junior works for schimmer, that opens doors (off the top I can think of 2 recent associates of his that now work buyside at Viking and a prominent crossover fund). For some of the more jr folks, undergrads etc. just goes to show how off base WSO comments can be

 

Lmao bro doesn’t know anything about the industry. Goldman Sachs biotech is a joke. JPM is decent and MS also didn’t have a top II ranked analyst.

 

Agree. Biotech is its own thing and imo best research comes out of (not in order) Leerink, TD Cowen, LifeSci capital, and Stifel. 
 

The BBs research is pretty crap tbh. Very very rarely do you get alpha from them. The other banks I mentioned actually do quality stuff from the stuff I’ve read. I read most of those banks work regularly if relevant companies. 

 

Suscipit impedit quaerat consequuntur eum omnis omnis. Officia qui facilis quo voluptatem fugiat explicabo quasi. Commodi laboriosam sequi aliquid aliquid et qui nihil.

Iure et est tenetur dolorem et. Quisquam non rerum aut. Impedit quae dolores et. Molestiae quo laborum voluptates delectus laboriosam.

Dolorem iusto voluptates expedita culpa voluptates sed asperiores mollitia. Consectetur officiis sapiente illum sed et neque voluptatem. Nulla sequi aut ut minus.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (87) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
Secyh62's picture
Secyh62
99.0
5
GameTheory's picture
GameTheory
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
kanon's picture
kanon
98.9
9
Linda Abraham's picture
Linda Abraham
98.8
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”